

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS FINANCE CORPORATION	03/01/2004
RECEIVING PARTY DATA	
Name:	SYNGENTA INVESTMENT CORPORATION
Street Address:	2200 Concord Pike
City:	Wilmington
State/Country:	DELAWARE
Postal Code:	19803
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	5958835
CORRESPONDENCE DATA	
Fax Number:	(336)632-2012
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(336) 632-7586
Email:	pamela.shirling@syngenta.com
Correspondent Name:	Syngenta Crop Protection, Inc.
Address Line 1:	410 Swing Road
Address Line 4:	Greensboro, NORTH CAROLINA 27409
NAME OF SUBMITTER:	Thomas Hamilton
Total Attachments: 3 source=Syngenta Investment Assignment#page1.tif source=Syngenta Investment Assignment#page2.tif source=Syngenta Investment Assignment#page3.tif	

CH 5958835 \$40.00

500012313

PATENT
 REEL: 015377 FRAME: 0868

ASSIGNMENT

Whereas, Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in each of the United States patents listed in Appendix B; and


Whereas, in accordance with a resolution of its Board of Directors made on October 31, 2000, Novartis Finance Corporation wishes to assign its entire interest in each of the United States patents listed in Appendix B and in certain related United States patents and patent applications to Syngenta Investment Corporation, 2200 Concord Pike, Wilmington, DE 19803, a corporation of Delaware, and said Syngenta Investment Corporation wishes to acquire Novartis Finance Corporation's interest in said patents and patent applications.

Now, therefore, Novartis Finance Corporation hereby assigns to Syngenta Investment Corporation and its successors and assigns its entire right, title and interest in (1) (a) each of the three hundred thirty-five (335) United States patents listed in Appendix B, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents) and (2) (a) any and all United States patent applications, whether pending or abandoned, that are continuations and divisions (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations) of the applications which issued as the patents listed in Appendix B, (b) any and all United States patents that may have been or, in the future, that may be issued and/or granted on all of said applications, (c) any and all applications for reissues of said patents, (d) any and all reissues of said patents that may be issued and/or granted, (e) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (f) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including, in the case of all patents (including reissue patents) within the scopes of (1) and (2), the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Finance Corporation to Syngenta Investment Corporation constituting the entire right, title and interest in said patents (including reissue patents), applications, extensions and reexamination certificates.

In witness whereof, Novartis Finance Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 1st day of March 2004.

Novartis Finance Corporation



Wayne P. Merkelson
Vice-President

Appendix B

4,600,428	4,886,887	5,120,741	5,430,188
4,601,745	4,888,348	5,135,927	5,436,248
4,602,936	4,897,109	5,153,200	5,439,912
4,603,211	4,897,396	5,166,153	5,446,154
4,605,656	4,897,424	5,166,430	5,447,935
4,608,372	4,900,827	5,169,951	5,447,945
4,612,037	4,902,340	5,175,293	5,451,595
4,612,395	4,904,778	5,179,094	5,457,276
4,618,360	4,908,467	5,183,492	5,466,785
4,623,382	4,914,098	5,190,928	5,477,002
4,629,810	4,918,088	5,194,628	5,478,958
4,632,695	4,918,230	5,204,100	5,481,013
4,671,819	4,919,704	5,209,771	5,484,918
4,674,229	4,919,935	5,217,871	5,489,695
4,681,619	4,921,980	5,232,898	5,493,032
4,686,294	4,925,840	5,237,084	5,496,848
4,692,524	4,925,842	5,245,040	5,506,099
4,693,741	4,925,876	5,250,556	5,508,184
4,693,745	4,931,439	5,250,557	5,508,402
4,705,800	4,931,560	5,250,559	5,514,795
4,707,182	4,931,581	5,254,739	5,514,816
4,709,092	4,935,051	5,262,386	5,519,026
4,727,186	4,938,797	5,266,554	5,519,125
4,729,190	4,939,257	5,266,585	5,521,153
4,753,954	4,944,790	5,274,100	5,521,195
4,758,667	4,948,798	5,276,186	5,523,311
4,759,793	4,952,726	5,280,041	5,527,760
4,766,253	4,958,030	5,281,718	5,527,917
4,780,125	4,959,096	5,286,709	5,530,195
4,780,551	4,962,126	5,296,449	5,536,726
4,798,688	4,968,344	5,302,605	5,536,900
4,810,724	4,978,383	5,302,607	5,538,979
4,812,164	4,989,741	5,310,721	5,541,148
4,831,148	4,992,434	5,322,853	5,541,310
4,833,255	4,996,325	5,324,842	5,545,630
4,847,258	4,997,941	5,332,717	5,552,368
4,849,007	4,997,967	5,350,689	5,554,619
4,849,009	5,002,604	5,373,013	5,556,828
4,849,219	5,002,606	5,384,321	5,558,997
4,851,028	5,023,259	5,384,403	5,559,034
4,851,031	5,023,333	5,384,416	5,561,230
4,853,396	5,041,603	5,397,697	5,567,705
4,854,963	5,049,571	5,399,545	5,583,249
4,857,100	5,063,236	5,403,814	5,585,238
4,859,229	5,075,316	5,403,844	5,585,519
4,861,787	5,075,443	5,407,934	5,595,733
4,866,079	5,077,311	5,409,823	5,596,131
4,870,184	5,082,860	5,412,107	5,597,779
4,872,902	5,102,445	5,420,301	5,597,840
4,881,964	5,104,440	5,430,034	5,599,771
4,881,966	5,112,849	5,430,035	5,599,828

Appendix B

5,601,847	5,731,266	5,925,367
5,606,057	5,731,267	5,929,102
5,610,042	5,731,500	5,942,662
5,610,044	5,731,501	5,945,437
5,612,288	5,731,502	5,955,274
5,614,395	5,731,506	5,955,362
5,625,071	5,758,766	5,958,835
5,625,136	5,759,561	5,981,582
5,627,188	5,763,481	5,990,383
5,631,007	5,766,900	6,017,850
5,637,763	5,767,369	6,017,851
5,639,949	5,770,450	6,018,105
5,641,666	5,770,696	6,034,083
5,641,882	5,770,758	6,048,824
5,643,360	5,780,469	6,057,490
5,643,774	5,783,704	6,066,596
5,645,169	5,789,214	6,071,698
5,646,145	5,792,904	6,083,881
5,646,157	5,800,997	6,091,004
5,646,288	5,804,693	6,103,667
5,648,383	5,814,453	6,107,279
5,648,487	5,814,629	6,107,544
5,650,505	5,817,502	6,117,670
5,650,517	5,817,602	6,117,892
5,654,414	5,830,899	6,130,236
5,659,124	5,831,114	6,137,033
5,662,898	5,837,290	6,147,282
5,663,176	5,840,868	D361,509
5,663,383	5,843,982	D364,956
5,670,350	5,846,571	End
5,674,514	5,847,147	
5,679,560	5,847,258	
5,679,623	5,849,870	
5,686,282	5,851,766	
5,686,283	5,852,012	
5,686,295	5,856,154	
5,686,600	5,859,300	
5,688,939	5,859,335	
5,689,044	5,859,336	
5,693,774	5,866,153	
5,698,425	5,866,326	
5,710,031	5,869,719	
5,714,599	5,872,212	
5,716,849	5,877,012	
5,721,364	5,880,328	
5,723,491	5,882,869	
5,723,721	5,883,283	
5,723,759	5,888,801	
5,728,875	5,889,174	
5,728,922	5,891,688	
5,728,923	5,912,375	